KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.

Xiao-Qiang Liu, Yang-Yang Qi, Tao Huang, Li-Li Huang, Ming-Xuan Zhao, Zhong-Fang Wang, Jun Dai, Yan-Xia Wang, Jing-Jing Chen, Xiao-Yun Yang, Hui-Lan Fan, Xue-Mei Yan, Jian-Chang He, Yan-Xiang Zou, Zhi-Wei Jiang, Zhi-Fei Zhan, Si-Wen Tao, De-Fang Dai, Feng Shi, Qiong-Na Zhang, Xiu-Liang Yang, Xiao-Zhong Li, Wei Li, Jing Lu, Jiang-Bing Zheng, Zhi-Hua Zhang, Gao-Xiang Chen, Hong Su, Wei-Min Gao, Lorenz von Seidlein, Xuan-Yi Wang, Lin Yuan, Jin-Zhong Lin

Hum Vaccin Immunother 21(1) 2502250

PMID40376714
PMCIDPMC12087488
DOI10.1080/21645515.2025.2502250
发表日期2025-05-16
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

A randomized, double-blind, controlled phase 3 trial was conducted during a COVID-19 outbreak after the initial, stringent zero-Covid policy was relaxed in three provinces. Eligible adults aged ≥18 years who had received three doses of inactivated COVID-19 vaccines 6 months earlier were randomly assigned in a 1:1 ratio to receive either one intramuscular injection of RQ3013 or ZF2001 vaccine. The primary end point was protection against PCR-confirmed symptomatic SARS-CoV-2 infection with onset at least 7 days after the booster. A total of 3,167 and 3,169 eligible participants received one dose of RQ3013 or ZF2001 vaccine, respectively. COVID-19 illness was confirmed in 91 participants in the ZF2001 group (11.8 per 100 person years; 95% confidence interval [CI]: 9.6-14.6) and in 45 participants in the RQ3013 group (5.7 per 100 person-years; 95% CI: 4.3-7.7) during a 4-month follow-up, resulting in a relative efficacy of 51.7% (95% CI, 30.9-66.2%) (p < .001) in an intention-to-treat analysis. The RQ3013 vaccine was also found to be significantly more immunogenic against omicron BA.5 compared to the ZF2001 vaccine. Moderate, transient adverse reaction after vaccination occurred more frequently in the RQ3013 group than in the ZF2001 group. Serious adverse events (SAEs) were rare and occurred almost equally in two groups. All SAEs were not related to the vaccination. These findings suggest that a chimeric mRNA vaccine design involving multiple antigenic epitopes provides broader protection across subvariants and variants of SARS-CoV-2 than the subunit vaccine ZF2001.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2a

Figure 2a. Efficacy of RQ3013 vs . COVID-19 in the mITT population.

Figure_2a

Cumulative Event Rate

Figure 2a · Panel Figure_2a

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Figure_2a 是同一 Figure 2a 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 2b

Figure 2b. Efficacy of RQ3013 vs . COVID-19 in the per-protocol population.

Relative_Efficacy

COVID-19 infection

Figure 2b · Panel Relative_Efficacy

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Relative_Efficacy 是同一 Figure 2b 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Assembly of participants.
非 KM Figure
Figure 3aFigure 3a. Virus-neutralizing titers pre- and post-booster (all participants in immunogenicity subset).
非 KM Figure
Figure 3bFigure 3b. Virus-neutralizing titers pre- and post-booster (susceptibles in immunogenicity subset).
非 KM Figure
Figure 4Figure 4. Solicited local and systemic adverse events.
非 KM Figure
Figure 4Figure 4. (Continued).
非 KM Figure